FDA approvedGH axisMetabolic

Tesamorelin

Egrifta / Stabilized GHRH / GHRH analogue

The most clinically validated GHRH analogue available. FDA-approved for visceral fat reduction. Emerging data for cognitive protection in early Alzheimer's and MCI. Widely prescribed off-label for body composition and longevity.

Evidence

Phase III / FDA approved

Routes

injectable

Available since

FDA approved 2010. Off-label compounding use widespread from approximately 2012.

Mechanism of action

Stabilized synthetic GHRH that binds pituitary receptors more potently than Sermorelin. Increases GH and IGF-1 driving visceral fat reduction. Direct cognitive effects via IGF-1 in the brain under active investigation in NIH-funded trials.

Effects in the body

Tesamorelin is the most potent and proven GHRH analogue. Its approval came through HIV research but the mechanism applies broadly. Now being studied for early Alzheimer's and MCI with promising preliminary results from multiple academic centers.

Pros & cons (from the literature)

Pros

FDA-approved with full Phase III clinical data
Clinically proven visceral fat reduction
Cognitive protection signals emerging in MCI trials
Better tolerated than exogenous GH
Well-characterized safety profile after years of clinical use

Cautions

Expensive as brand Egrifta at $1,500–$2,000 per month
May elevate blood glucose — caution in diabetes
Joint pain and water retention at higher doses
Off-label for non-HIV indications

Protocol summary (from published research)

2 mg subcutaneous injection once daily at bedtime in the approved indication. Compounded off-label dosing varies by physician. Typical research cycles 3–6 months continuous with periodic metabolic monitoring.

Dosing ranges reproduced from published research literature. Not a prescription, not medical advice.

FDA & regulatory status

FDA-approved for HIV-associated lipodystrophy (brand name Egrifta). Widely prescribed off-label for body composition and cognitive function. Legally compoundable at significantly lower cost than brand.

Evidence base

Multiple Phase III RCTs completed. Emerging Alzheimer's and MCI data from NIH-funded trials. Falutz et al. 2010 NEJM primary approval paper.

Primary research sources

Peer-reviewed literature referenced throughout this profile is drawn from PubMed, Cell Metabolism, and clinical trial registries cited in the evidence base above.

Expert perspective — Dr. Alex Tatem, Urologist

Dr. Alex Tatem is a board-certified Urologist and Men's Health Specialist who has studied peptides for 12 years. Videos featured for educational purposes. ThePeptide.expert is an independent platform.

A board-certified physician explains Tesamorelin — the only FDA-approved peptide specifically studied for visceral fat reduction. Covers the clinical evidence, mechanism, and what the research shows.

Important. ThePeptide.expert summarizes published research. We are not a pharmacy, do not prescribe, and make no therapeutic claims. Regulatory status varies by jurisdiction.